Soleno Therapeutics (SLNO) Current Assets (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Current Assets data on file, last reported at $326.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $326.4 million, up 5.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $326.4 million (up 5.65% YoY), and the FY2025 annual result was $355.8 million, up 21.07% from the prior year.
• Current Assets eased to $326.4 million in Q1 2026 per SLNO's latest filing, from $355.8 million in the prior quarter.
• Over five years, Current Assets peaked at $534.9 million in Q3 2025 and troughed at $9.1 million in Q1 2023.
• A 5-year average of $185.8 million and a median of $171.4 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets sank 69.55% in 2023, then surged 1556.88% in 2024.
• A 5-year view of Current Assets shows it stood at $15.6 million in 2022, then surged by 995.15% to $171.4 million in 2023, then soared by 71.51% to $293.9 million in 2024, then climbed by 21.07% to $355.8 million in 2025, then retreated by 8.27% to $326.4 million in 2026.
• Business Quant data shows SLNO's Current Assets at $326.4 million in Q1 2026, $355.8 million in Q4 2025, and $534.9 million in Q3 2025.